Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study.
Tessoulin B, Harnett J, Cho SG, Taszner M, Kim TM, Novelli S, Villasboas JC, Merli M, Jiménez-Ubieto A, Poon M, Tucker D, Walewski J, Yi S, Song Y, Chong G, Bachy E, Guidez S, Alonso A, Jagadeesh D, Zhang W, Magnano Mayer L, Iskierka-Jażdżewska E, Tani M, Cai J, Ivanescu C, Reaney M, Chaudhry A, Mohamed H, Ambati S, Chi L, Kamat S, Luminari S; ELM-2 Investigators.
Tessoulin B, et al.
Clin Lymphoma Myeloma Leuk. 2025 Oct;25(10):e766-e777.e6. doi: 10.1016/j.clml.2025.05.017. Epub 2025 May 23.
Clin Lymphoma Myeloma Leuk. 2025.
PMID: 40571446
Free article.
Clinical Trial.
Median time to definitive deterioration (TTDD) was 22.4 months for GHS/QoL, 22.6 months for role functioning, 19.8 months for social functioning, 16.4 months for cognitive functioning, and not reached for physical functioning or emotional functioning. ...Most patien …
Median time to definitive deterioration (TTDD) was 22.4 months for GHS/QoL, 22.6 months for role functioning, 19.8 months for …